|
WO2021074418A1
|
|
Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
|
WO2021074414A1
|
|
Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
|
WO2021044063A1
|
|
Method for sequencing rna oligonucleotides
|
|
JP2020109092A
|
|
Mutant calreticulin for diagnosis of myeloid malignancies
|
|
WO2020079103A1
|
|
Method for identifying a chemical compound or agent inducing ubiquitination of a protein of interest
|
|
EP3808741A1
|
|
Compounds for targeted degradation of carrier proteins and uses thereof
|
|
EP3630122A1
|
|
Sulfonylurea compounds in the treatment of disease associated with uv-induced damage
|
|
AU2017359288A1
|
|
Combination of a BRD4 inhibitor and an antifolate for the therapy of cancer
|
|
EP3367098A1
|
|
Methods for determining interaction between biological cells
|
|
HUE047175T2
|
|
Methods for studying nucleic acids
|
|
WO2012130720A2
|
|
PREDICTION OF RESPONSIVENESS TO PIK3/mTOR INHIBITORS
|
|
WO2011098407A1
|
|
Microspheres
|
|
EP2533797A1
|
|
Complement factor h for oxidative stress disease conditions
|
